Knowledge of the number and kinds of differentiation steps that characterize cells of the osteoblast lineage is inadequate.
Introduction
Although it is generally accepted that the osteoblast originates from a mesenchymal stem cell which can give rise to a variety of cell and tissue types, including muscle, fat, cartilage, and bone (1-6), relatively little is known about the differentiation of osteoblasts from their progenitors. Moreover, on the basis of in vitro studies and clonal analysis, marked heterogeneity has been documented in bone cell populations and it is not clear whether this diversity arises from cells being at different stages of differentiationlmaturation or whether there is diversity in individual stages of the differentiated phenotype itself (7) (8) (9) . In part, understanding the osteoblast lineage and the sequence of steps from committed progenitor to terminally differentiated osteocyte has been hampered by a lack of sufficient phenotypic markers for osteoblastic cells and their precursors.
the cytoplasm, on the cell surface, and in the extracellular matrix. Of the antibodies selected, one identified both preosteoblasts and osteoblasts and has been found to be against alkaline phosphatase. The others recognized the mature osteoblasts, osteocytes, and chondrocytic cells. The pattern and distribution of the labeling in vivo extended to primary cells and cell lines in vivo. These results support earlier observations on molecules differentially expressed by cells at different stages of the osteoblast lineage and extend the available cell surface and cytoplasmic epitopes identifiable as marker Although antibodies against tumor antigens expressed on osteogenic sarcoma cells were first described several years ago, virtually none of them are reported to recognize antigens expressed on the normal osteoblast counterparts (see, e.g., [10] [11] [12] [13] [14] [15] . However, the possibility that cells at different stages of the osteoblast lineage might express antigenic determinants unique or distinctive to these stages has recently been made compelling by several reports. Using a chick osteoblastic cell model, Nijweide and Mulder (16) prepared a monoclonal antibody (MAb) reacting only with osteocytes, and Bruder and Caplan have recently reported a series of antibodies also apparently labeling different subpopulations of chick osteoblastic cells (17) (18) (19) . Furthermore, some molecules associated with bone matrix (e.g., osteopontin, osteocalcin) appear to be synthesized differentially by cells at earlier or later stages of differentiation We have begun to utilize hybridoma technology to investigate the osteoblast lineage. In this report we describe the isolation of MAb to bone cell subpopulations. The MAb were raised by injection of cell populations enriched for cells expressing osteoblast characteristics or ones in which bone formation itself had been stimulated. Antibodies of interest were selected from among positive hybridomas by screening on frozen sections of bone. A preliminary account of this work was presented as an abstract (23).
Materials and Methods

Cells and Cell Culture
Populations offetal rat calvaria (RC) cells were prepared by enzymatic digestion of calvariae from 21-day fetal Wistar rats as described (24) (25) (26) . The rat osteoblastic osteosarcoma cell lines UMR 106.06 (kindly provided by Dr. T. J. Martin) and ROS 17/23 (kindly provided by Dr. G. A. Rodan) were grown in high glucose-containing Dulbecco's modified Eagle's medium (HG-DME) and alpha-minimal essential medium (aMEM), respectively; both media were supplemented with 15 % heat-inactivated (30 min, 56'C) fetal bovine serum (Flow Laboratories, McLean, VA; Lot #9080063) and antibiotics (100 pg/ml penicillin G (Sigma; St Louis, MO); 50 pglml gentamycin (Sigma); 300 nglml fungizone (Flow). The human osteosarcoma cell line MG-63 was purchased from the American Type Culture Collection (Rockville, MD) and maintained in aMEM supplemented with 10% fetal bovine serum and antibiotics (as above).
For bone nodule formation in vitro, details of the culture procedures have been presented elsewhere (25.26) . Briefly, fetal rat calvariae cells were plated into 35-mm or 100-mm tissue culture dishes (Falcon 3001; Becton Dickinson Labware, Oxnard, CA) at a density of 3 x 103-104 cells per cm2 in aMEM containing 15% Cellect Silver fetal bovine serum (Flow) and antibiotics as above (standard growth medium) supplemented with 50 pg/ml ascorbic acid (Fisher Scientific; Fair Lawn NJ) (AA) and 10 mM sodium+-glycerophosphate (p-GP) (BDH Chemicals; Poole. UK) (supplemented medium) (Day 0). The next day (Day I), the medium was changed to supplemented medium. The medium was changed completely every 2 days. Cultures were maintained in a humidified atmosphere consisting of 95 % air and 5 % CO2 at 37°C (Forma Scientific, Marietta, OH; Model 33325-118) for up to 21 days.
Production of Antibodies
Three kinds of immunizing populations were used (see also Table 1 ). In one, the fourth population from enzymatic digestion of fetal rat calvaria cells (see 24, 25) isolated as above was grown until confluence in standard medium as above. In the second, cells were grown to confluence from explants of bone fragments remaining after collagenase digestion (27) . In the third, bone marrow stroma cells were prepared from adult male Wistar rats as described (28) (29) (30) . In the latter case, first subculture cells were plated at lo3 cells/cm2 in 150-cm2 round tissue culture dishes and grown in supplemented medium as above until bone nodules had begun to form, but before they were heavily mineralized. In all cases, for preparation for injection the cells were washed three times with PBS and recovered from the tissue culture dishes by gentle scraping, and then were pipetted repeatedly to form a largely single-cell suspension. Young female Balb/c mice were immunized with three or four consecutive injections of the cells. The immunization schedule involved an initial intraperitoneal injection of cells (10' cellsl0.2 mllmouse), followed by two or three similar injections at 3-week intervals. Three days after the final injection, spleen cells from immune mice were fused with the myeloma cell line SP2lO (31) (kindly provided by Dr. M. Shulman, Department of Immunology, University of Toronto), with 50% polyethylene glycol (PEG) (PEG 1000, Lot #59C-6079; Sigma) as fusion agent (32) (33) (34) . After fusion, cells were distributed in microtiter plates (Nunc; Roskilde, Denmark) in a volume of 200 pl/well in Dulbecco's modified Eagle's medium (DMEM-H21) (high glucose) supplemented with glutamine (20 mM), 2-mercaptoethanol (5 x lo-> M), and 15% heatinactivated defined bovine serum (Hyclone Lab, Logan, UT; Lot #2111726). Hybridomas were selected by growth in HATmedium as described (32, 33) . After 15-20 days of selection, supernatants from wells with growing cells were assayed by indirect immunofluorescence on fetal rat calvaria frozen sections (see below). Hybridomas selected for further study were cloned by limiting dilution at 0.5-1.0 cell per microtiter well and single-colony wells were again selected by indirect immunofluorescence. RBM 211 (subclone RBM 211.13), RBM 202 (subclone RBM 202.16), and RBM 208 (subclone RBM 208.6) were isolated in a fusion from mice injected with rat bone marrow stromal cells; RBM 407 (subclone RBM 407.5) was from an independent fusion from mice injected with different isolates of marrow stromal cells. RC4D 139 (subclone RC4D 139.12) and RCC 455 (subclone RCC455.4) came from two independent series of rat calvaria cell isolations, injection, and fusions, the former from population IV of enzymatic digestion, the latter from bone explants (see Table 1 for further details).
Subclass Determination
The isotype of the MAb was determined by immunoprecipitation using immunodiffusion plates (The Binding Site, University of Birmingham Res. Inst., Birmingham, UK; Lot #T2580) according to the manufacturer's instructions.
Screening Assay for Selection of Antibodies
To screen for hybridomas producing antibodies that recognized osteoblastic cells, supernatants from wells with good hybridoma growth were screened on frozen sections prepared from fetal rat calvariae. Calvariae were removed 
Immunofluorescence
Frozen Sections. Cryostat sections were air-dried for 30 min at room temperature, fixed in 1-3.7% (v/v) formaldehyde (Fisher) in PBS for 5 min at room temperature, and post-fixed in -2O'C methanol for 5 min. The sections were rinsed three times in PBS and then incubated with 3% bovine serum albumin (BSA) (w/v; essentially fatty acid-free Lot#28F-O856; Sigma) prepared by heating at 80°C for 3 min in PBS. The sections were incubated with the BSA solution for 1 hr at 37°C to block nonspecific binding of FIX-conjugated second antibodies and rinsed three times in PBS. Control experiments indicated that BSA treatment did not affect the binding of the MAb described here but did diminish nonspecific background from second antibodies. Sections were then overlaid with antibodies. Culture supernatants were used undiluted, unpurified ascites fluids were diluted 1900 in PBS, and affinity-purified ascites fluid was diluted 1:lOO in PBS. Control sections were incubated with PBS or myeloma culture supernatant or with unrelated hybridoma supernatant in lieu of test antibodies. After incubation for 30 min at room temperature, the sections were rinsed with PBS and incubated with FIX-conjugated affinity-purified F(ab')z fragments of sheep anti-mouse IgG (NEN, Boston, MA; Lot #FF'J-084) (k75 dilution in PBS) for 30 min at room temperature. Sections were rinsed with PBS, mounted with Moviol (Hoechst; Montreal, Quebec, Canada) and viewed on a Zeiss Photomicroscope 111 (Zeiss; Oberkochen, Germany) equipped with epifluorescence filters. Photographs were taken using Kodak (Eastman Kodak; Rochester, NY) T-Max 400 ASA or P3200 ASA films and developed with Kodak T-Max developer.
Cultured Cells. Immunofluorescence on cultured cells was done essentially as described (35) . Briefly, cell suspensions were plated onto sterile 12-mm round glass coverslips (Bellco; Vineland, NJ) and cultured to the desired densities in media as above. Cells were then fixed with 1.5% (v/v) formaldehyde (Fisher) in PBS for 5 min at room temperature, followed by -20°C methanol for 5 min. After fixation, cells were rinsed three times with PBS, and antibodies were added (hybridoma culture supernatants were full strength; unpurified and purified ascites fluid was at 1:100-1:1000 dilutions in PBS) and incubated for 30 min at room temperature in a humidified chamber. Controls were as above. After incubation with first antibody, the cells were washed three times with PBS and were then incubated with FIX-conjugated affinity-purified F(ab')l IgG as above. The cells were washed three times with PBS, mounted, and screened as above.
Results
Selection of Hybridomas
The antibodies reported here were selected from a series of four different injection sequences as outlined in Table 1 . Detailed characterization of the rat cell populations used for injection has been reported elsewhere. Briefly, populations were prepared and grown in vitro under conditions in which bone formation was maximally stimulated (Fusion 1 and 2; for culture details see [28] [29] [30] 
Immunostaining in Bone, Bone Ceh, and Non-bone Tissue
To determine whether the labeling was restricted as described, we treated sections either before or after fixation with collagenase, hyaluronidase, trypsin, or pronase, treatments that might expose cryptic epitopes. Without fixation, tissues tended to lose their integrity after enzyme treatment; however, within the limits of detectability, none of these treatments exposed new epitopes or obliterated the bone cell-associated staining described (not shown). Bone In Vivo. Staining of frozen sections of rat calvaria with periosteum, soft connective tissue, and skin intact ( Figure 1A) showed that RCC455.4 labeled very intensely the osteoblasts along the bone surface and osteocytes, and less intensely but above control in most or all cells in the periosteum and soft connective tissue ( Figures 1B and 1E ). Neither the epithelium of the skin nor the bone matrix itself was labeled. RBM 211.13, on the other hand, stained only osteoblasts, a small proportion of the osteocytes, and labeled pre-osteoblasts in the region three to four cell layers out from the bone surface but did not label bone matrix, cells in soft connective tissue, or epithelium ( Figure 1C Staining of the fibrous sagittal suture area between the parietal bones also reflected the differences between the antibodies. RBM 211.13 labeled only periosteal cells close to the bone surfaces and virtually no other cells in the suture (Figure 2A ). Because the staining pattern with RBM 211.13 was reminiscent of that for the osteoblastassociated enzyme alkaline phosphatase, we compared the histochemical staining for that enzyme ( Figure 2D ) with that of RBM The observations are presented on a subjective scale of intensity of staining. -, not labeled above background in controls; * , very weak labeling above background, + , distinctly above background but not intense; + + , intense labeling; + + + , very intense labeling.
211.13; the staining patterns were virtually coincident. In other studies, which included immunoblotting and immunoprecipitation, we have confirmed that RBM 211.13 recognizes alkaline phosphatase (36) . In contrast to RBM 211.13, RCC 455.4 labeled cells throughout the suture to almost the same intensity as the osteoblasts and osteocytes, i.e., more intensely than the cells of other fibrous connective tissues ( Figure 2B ). Similarly, RC4D 139.12 also labeled most or all of the cells of the sutural area as intensely as These results indicate staining of the cultures by enzyme histochemistry.
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" Biopsies of human osteosarcomas were obtained from Dr. C. Birek, M t Sinai Hospital Research Institute, Toronto, Ontario, Canada. it stained the osteoblasts and osteocytes and with the same distinct punctate appearance ( Figure 2C ). RBM 202.16, RBM 407.5, and RBM 208.6 also stained cells of the sutural area (not shown).
To establish whether bones formed by endochondral ossification (i.e., long bones) labeled equivalently to those formed by intramembranous ossification (i.e., calvariae), 21-day fetal rat metatarsal bones were also stained. The staining patterns were coincident with those expected based on the calvaria label. For example, RBM 211.13 labeled only the osteoblasts, periosteal cells, and hypertrophic chondrocytes ( Figure 3B ), whereas RCC45 5.4 labeled all chondrocytic cells and the osteoblasts very intensely ( Figure 3C ). Osteoclasts present in the bone sections were not labeled with the antibodies described here (not shown). Table 2 summarizes all the boneassociated staining in calvaria and metatarsal bones with these anti bodies.
Osteoblastic Cells and Bone Formed In Vitro. A major consideration in characterizing antibodies to putative differentiation antigens is whether the antibodies label cells in culture and tissue formed in vitro identically to their counterparts in vivo. Enzymatically isolated fetal rat calvaria (RC) cells are a frequently used in vitro model; the cells are osteoblastic, based on their expression of properties such as hormone response (e.g., parathyroid hormone-and prostaglandin E-sensitive adenylate cyclase), matrix synthesis (e.g., collagen Type I, osteopontin), and ability to make bone in vitro (for summaries see 6,8,37,38). All the MAb reported here stained RC cells, but the patterns and the percentage of positive cells in the populations were distinctly different. For example, RBM 211.13 labeled uniformly and diffusely the cell surface in fixed and permeabilized or unfixed and unpermeabilized cells ( Figure 4A ), consistent with its being against alkaline phosphatase. On the other hand, RCC455.4 labeled an intracellular antigen stainable only after permeabilization of the cells ( Figure 4D ). The latter antigen was present in a vesicular pattern. RC4D 139.12 was present both intracellularly and extracellularly in a pattern of large distinct dots or vesicles. Many large dots were stained primarily in a cell surfaceassociated pattern in fixed or unfixed, unpermeabilized cells (not shown), but these and similar intracellular vesicles were visible in permeabilized cells ( Figure 4G ). Notably, these same cell distributions were seen when the same antibodies were used to stain osteoblastic cells in vivo, i.e., the cell surface pattern was obvious with RBM 211.13 ( Figure 4C ), the intracellular vesicular pattern of RCC45 5.4 (Figure 4F) , and the dotty intracellular and extracellular pattern of RC4D139.12 ( Figure 41 ). Earlier, we (25, 39, 40) and others (41-43) have described the formation of nodules of bone in such isolated rodent calvaria cells cultured long term in vitro. Interestingly, the pattern of staining of the bone nodules in vitro was indistinguishable from that seen in vivo ( Figures 4B, 4E , and 4H). Table 3 summarizes the staining characteristics of our monoclonal antibodies on RC and other osteoblastic cells, including wellcharacterized clonal osteoblastic osteosarcoma lines and clonal cell lines prepared from normal bone and the stromal populations of bone marrow. For comparison, two human osteosarcoma lines and human osteosarcoma biopsy samples are also included, as are primary rat skin fibroblasts. Two of the antibodies, RCC 455.4 and RC4D 139.12, crossreact on human samples, but interestingly the RCC 455.4 antigen is absent from the MG-63 osteosarcoma cell line. None of the antibodies except RCC 455.4 labels rat skin fibroblasts, consistent with the low intensity staining of RCC 455.4 on fibrous connective tissues (see above). Also of interest is the fact that whereas the rat osteosarcoma line ROS 17/23 labels with RC4D 139.12, RBM 202.16, and RBM 208.6, the rat osteosarcoma line UMR 106.06 does not.
Immunostaining in Other Non-bone Tissues In Vivo. In preparing frozen sections of both calvaria bones and long (femur, metatarsal) bones, we left other surrounding non-bone tissues intact and the immunostaining indicated that some of the antibodies stained a limited number of tissues other than bone. For example, as indicated above, RC4D 139.12 intensely labeled striated muscle both of the head ( Figure 1H ) and associated with the femur (not shown). To determine how widespread the various epitopes were, we prepared frozen sections from a variety of other tissues; the tissue stain- ing is summarized in 'Etble 4. Because RBM 211.13 recognizes alkaline phosphatase and because the bone isoenzyme is the same as the liver and kidney isoenzyme, we screened liver and kidney and compared fetal and adult tissue, since both fetal and adult cells had been used in the different immunization schemes (Table 1) . RBM 211.13, made against adult bone cells, labeled either adult or fetal alkaline phosphatase-expressing cells (Table 3) ; as expected, it did not stain fetal kidney but did label the collecting ducts but not the glomeruli of adult kidney ( Figure 5E ). RCC 45 5.4, made against fetal cells, labeled neither adult nor fetal kidney (not shown). RC4D 139.12, made against fetal bone cells, labeled both adult and fetal bone cells in culture ('Etble 3). RC4D 139.12 labeled the collecting ducts of fetal and adult tissue in the punctate pattern typical for this antibody. Whereas RBM 208.6 did not label fetal or adult kidney, both RBM 407.5 and RBM 202. 16 labeled fetal and adult kidney. In the fetal tissue, both labeled the collecting tubules ( Figures 5C and TD) , while in the adult RBM 407.5 labeled all the collecting ducts and glomeruli ( Figure 5G ) and RBM 202.6 labeled the glomeruli and only the cortical collecting ducts ( Figure 5F ).
In liver, RBM 211. 13 labeled a few cells in both fetal ( Figure  6F ) and adult tissue, corresponding to the histochemical staining for alkaline phosphatase (not shown). RC4D 139.12 labeled all fetal hepatocytes with its typical punctate pattern ( Figure 6C ), but the staining was very dim and in adult the hepatocytes were also labeled but even dimmer (not shown). Both RBM 202. 16 ( Figure  6D ) and RBM 407.5 labeled all hepatocytes in fetal sections, but labeled primarily the perivenous hepatocytes in the adult ( Figure  6H ). lU3M 208.6 labeled a few scattered hepatocytes around the centrilobular vein in fetal tissue ( Figure 6E) and labeled a few scattered hepatocytes in the adult (not shown).
Ofthe other tissues screened, only RC4D 139. 12 and RBM 202.16 labeled brain and both labeled in the dentate gyrus (not shown). Interestingly, in adult intestine RBM 407.5 labeled epithelial cells whereas RBM 202. 16 did not. All of these staining results are summarized in Table 4 .
Discussion
In this report we describe the preparation of six MAb that were raised against rat cells and express osteoblast-associated staining both in vivo and in vitro. Of the antibodies raised, several different patterns of reactivity were evident, but at least as far as the osteoblastic populations go, the staining of isolated cells or bone formed in vitro appeared identical to that seen in vivo. Although such data on expression of cell surface or cytoplasmic antigens do not in themselves constitute proof of a cell lineage relationship, it appears that the system we are utilizing will be a useful one to investigate further aspects of osteoblast differentiation.
Mixed populations of cells, comprising populations enriched for osteoblast properties or for ability to form bone in vitro, were used as antigens. All the antibodies were then selected for boneassociated staining on sections in which not only bone but other tissues were present. This allowed us to discard the majority of the antibodies which, although they labeled osteoblastic cells, also labeled several or all other tissues in the head sections. This sort of antibody comprised the overwhelming majority of antibodies raised.
For example, in the fusions summarized in Table 1 which were typical of the fusions we have done over a period of several years, more than 99% of the antibodies were to common and housekeeping molecules, including many to cytoskeletal proteins. The ability to select for the apparently rare rat differentiation antigens by injection into mice thus counterbalanced the rather tedious nature of a screen on frozen sections.
Of the antibodies raised, only one (RBM 211.13) intensely labeled cells in the pre-osteoblast zone as well as mature osteoblasts on the bone surface. Various aspects of the staining characteristics with this antibody, both in bone and in non-bone tissues including kidney and liver, led us to predict that this antibody might recognize the bone-liver-kidney isoenzyme of alkaline phosphatase. Indeed, the staining with RBM 211. 13 and that for alkaline phosphatase detected by a histochemical technique were virtually coincident. In other studies we have used immunoblotting and immunoprecipitation to confirm that RBM 2 11.13 indeed recognizes alkaline phosphatase and is probably recognizing an epitope carbohydrate in nature (36) . In keeping with our aim to attempt to delineate steps in the osteoblast lineage using such antibodies, we have panned and sorted subpopulations from mixed fetal rat calvaria populations with RBM 211.13. Unexpectedly, we were able to separate osteoprogenitor cells forming bone in vitro in the absence of glucocorticoids from those requiring glucocorticoids to form bone in vitro (36). Thus, not only positive immunoselection for the alkaline phosphatase positive osteoblastic cells but also negative immunoselection for cells not expressing the antigen will be a useful technique not only for RBM 211.13 but possibly also for the other antibodies recognizing cell surface determinants.
Of the other antibodies raised, intense staining of mature osteoblasts and osteocytes characterized the bone-related staining. However, in this regard, no two of the other antibodies were identical in their staining distributions. Of these antibodies, RBM 407.5 and RBM 202. 8 were the most similar to each other, but they were not identical (see Xbles 3 and 4). These two antibodies clearly recog nize a cell surface epitope shared by osteoblasts, osteocytes, and at least certain epithelial cells. Whether this is serendipitous labeling of a common epitope present on two different macromolecules or whether it reflects the presence of a macromolecule common to both differentiated osteoblastic and epithelial cells awaits further analysis. That such common osteoblast-epithelial markers may exist, however, is evident from the studies done on osteopontin, a non-collagenous protein of bone matrix (for review see 44) . Osteopontin, in addition to being expressed by osteoblasts, is synthesized by certain epithelial cells (20-22) . The cell and tissue labeling we have already done appears to preclude the molecule recognized by these two antibodies as being osteopontin; however, we have not yet completed a full characterization of the molecules. RBM 208.6 and RCC 455.4 both label cytoplasmic antigens in a vesicular pattern in mature osteoblasts and osteocytes. However, neither the labeling of different osteoblastic lines nor the presence of the epitopes in other tissues is the same for these antibodies (Tables 3 and 4). Characterization of the epitopes recognized by these antibodies is under way and supports the conclusion that they recognize different osteoblast-associated molecules. In this regard, preliminary data with RCC 455.4 are of interest. The molecule recognized by this antibody is, as cell and tissue staining indicates, present
